ERHVERVSSTYRELSEN

-3 JULI 2015

Ekspeditionen

Actavis Nordic A/S

Central Business Registration no. 17 55 77 42

Annual Report for 2014

The Annual Report was presented and adopted at the Annual General Meeting of the Company on 03/07 2015

Chairman

Peter Løvgren, Advokat

LEGARIS ADVOKATANPARTSSELSKAB
STRAERUPVEJ 8
DK-5683 HAARBY
DENMARK

Contents

	Page
Management's Statement and Auditors' Report	
Statement by Management on the annual report	1
Independent Auditor's Report	2
Management's Review	
Company Information	4
Financial highlights	5
Management's review	6
Financial Statements	
Accounting policies	10
Income statement 1 January - 31 December	16
Balance sheet at 31 December	17
Notes to the annual report	19

Statement by Management on the annual report

Today, the Executive Board and Board of Directors have discussed and approved the annual report of Actavis Nordic A/S for the financial year 1 January - 31 December 2014.

The annual report has been prepared in accordance with the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2014 and of the results of its operations for the financial year 1 January - 31 December 2014.

In our opinion, Management's Review includes a fair review of the matters dealt with in the Management's review

We recommend the adoption of the annual report at the annual general meeting.

Gentofte, 3 July 2015

Executive Board

Henriette Sidenius
CEO

Board of Directors

Fabian Alexander Hopkins
Chairman

Ólöf Thorhallsdottir

David Vrhovec

Helena Bergström

Statement by Management on the annual report

Today, the Executive Board and Board of Directors have discussed and approved the annual report of Actavis Nordic A/S for the financial year 1 January - 31 December 2014.

The annual report has been prepared in accordance with the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2014 and of the results of its operations for the financial year 1 January - 31 December 2014.

In our opinion, Management's Review includes a fair review of the matters dealt with in the Management's review

We recommend the adoption of the annual report at the annual general meeting.

Gentofte, 3 July 2015

Executive Board

Henriette Sidenius
CEO

Board of Directors

Fabian Alexander Hopkins
Chairman

Ólöf Thorhallsdottir

David Vrhovec

Helena Bergström

Independent Auditor's Report

To the Shareholder of Actavis Nordic A/S

Report on the financial statements

We have audited the financial Statements of Actavis Nordic A/S for the financial year 1 January - 31 December 2014, which comprise summary of significant accounting policies, income statement, balance sheet and notes, for the Company. The financial statements are prepared in accordance with the Danish Financial Statements Act.

Management's Responsibility for the financial statements

The Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act and for such internal control as the Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on the financial statements based on our audit. We conducted our audit in accordance with International Standards on Auditing and additional requirements under Danish Audit regulation. This requires that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation of financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Management, as well as the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

The audit has not resulted in any qualification.

Opinion

In our opinion, the financial statements gives a true and fair view of the Company's financial position at 31 December 2014 and of the results of the Company's operations for the financial year 1 January - 31 December 2014 in accordance with the Danish Financial Statements Act.

Independent Auditor's Report

Statement on Management's review

Pursuant to the Danish Financial Statements Act, we have read the Management's review. We have not performed any further procedures in addition to the audit of the financial statements. On this basis, it is our opinion that the information provided in the Management's review is consistent with the Financial Statements.

Hellerup, 3 July 2015

PricewaterhouseCoopers
Statsautoriseret Revisionspartnerselskab

Martin Lunden
State Authorised Public Accountant

Thomas Lauritsen
State Authorised Public Accountant

Company Information

The Company	Actavis Nordic A/S Ørnegårdsvej 16 2820 Gentofte	
	Central Business Registration no.:	17 55 77 42
	Financial Period:	1 January - 31 December
	Municipality of reg. office:	Gentofte
Board of Directors	Fabian Alexander Hopkins, Chairman Òlöf Thorhallsdottir David Vrhovec Helena Bergström	
Executive Board	Henriette Sidenius, CEO	
Auditors	PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab Strandvejen 44 2900 Hellerup	

Financial highlights

5-year summary:

Key figures	2014 Mio. DKK	2013 Mio. DKK	2012 Mio. DKK	2011 Mio. DKK	2010 Mio. DKK
Profit/loss					
Revenue	357	359	319	373	521
Operating profit/loss	4	-15	-18	33	30
Net financials	-20	-189	-1.489	-98	-39
Profit/loss for the year	-16	-202	-1.499	-65	-7
Balance sheet					
Balance sheet total	330	414	710	1.795	1.852
Investment in property, plant and equipment	0	0	0	0	0
Equity	-21	-9	-1.219	18	83
Number of employees	0	0	0	0	0
Financial ratios					
Gross margin	1,1%	-4,2%	-5,6%	8,8%	5,8%
Solvency ratio	-6,4%	-2,2%	-171,7%	1,0%	4,5%
Return on equity	106,7%	32,9%	249,6%	-128,7%	-8,1%

The ratios have been prepared in accordance with the recommendations and guidelines issued by the Danish Society of Financial Analysts. For definitions, see under accounting policies

Management's review

Main activity

The objective of the Company is trading in pharmaceuticals and investment in companies trading in pharmaceuticals. Furthermore, the Company carries out related activities, including the ownership of product rights.

Geographically, the Company's activities are primarily aimed at the Nordic countries.

Error in previous years

Comparative figures for 2013 are restated as a result of a grant of DKK 43.8 million received in connection with acquisition of a subsidiary. The grant has historically been classified as debt to group enterprises, but should have been recognised as a grant over equity. This is corrected as an error in previous years, and had the following effect:

TDKK	Annual Report 2013	Restated
Equity	-52,707	-8.944
Long-term debt	368.668	324,905

The reclassification had no effect on the income statement og total assets.

Development in the year

The income statement of the Company for 2014 shows a loss of TDKK 16.020 and at Dec 31, 2014 the balance sheet of the Company shows equity of TDKK -21.137. This is primarily related to income from investments in subsidiaries.

During 2014, the completion of the divestment of Actavis B.V. took place through the transfer of GM Invest B.V's shares from Actavis Nordic A/S (399 shares) and Actavis Group ehf. (1 share) to Actavis Dutch Holding B.V.

On Dec 12, 2014, the merger was effective between Actavis Nordic A/S and Colotech A/S, with the surviving entity being Actavis Nordic A/S.

On November 17, 2014, Actavis plc and Allergan Inc. reached an agreement to combine the two companies. On Mar 17, 2015 the combination was completed. The acquisition of Allergan is not expected to have any material impact on the financial statements for Actavis Nordic A/S.

Special risks – operating risks and financial risks

The financial statements are not affected by special risks.

Management's review

Expectations for the year ahead

The Company expects improved results from ordinary activities in the future, but any profit/loss will primarily depend on the capital and financing structure of the Company.

Research and development activities

The Company's development activities comprise registration of new products for the Group. The Company does not develop new products.

Corporate social responsibility

The Actavis Group's primary contribution to society relating to corporate social responsibility is that the Group produces and distributes generic pharmaceuticals which contribute to reducing countries' and citizens' expenditures for medical treatments.

Actavis constantly strives to especially secure consistency in supply of vital medicine to customers.

The Actavis Board of Directors and Executive Board are responsible for the Actavis Group's corporate social responsibility activities. Actavis' management team is accountable for the development and implementation of programmes which support the Group's ambition to contribute to health and increased quality of life in the countries where the Group operates.

Furthermore, the Actavis Group seeks to operate all aspects of its business in a safe and responsible manner that protects the environment and promotes the health & welfare of employees and the surrounding communities. This is carried out through a Corporate Environment, Health & Safety (EHS) organisation, introducing and implementing initiatives where appropriate to support the Actavis Group companies in complying with strategic objectives. Among other things, those initiatives include external certification and energy management policies. By nature, such initiatives are primarily implemented at production sites, which the Actavis Group does not have in Denmark. For this reason, Actavis Nordic A/S has a reduced impact on the external environment.

Policies and procedures

Actavis operates in geographically diverse regions and has therefore set out policies and procedures which are considered minimum standards for Actavis companies to implement. A "Corporate Manual" has been developed which contains integrated quality and EHS requirements for Actavis sites.

Management's review

Actavis supports and works to ensure that the spirit and intent of Equal Employment Opportunity is practiced in all aspects of the personnel activity, including recruitment, hiring, training, promotion, demotion, transfer, layoff, terminations, recall, granting of leaves of absence, rates of pay or other forms of compensation and selection for training of all individuals in all positions.

All employees are treated equitably during their employment and all actions will be taken without regard to race, creed, color, age, religion, sex, citizenship status, national origin, sexual orientation, marital status, medical condition, mental or physical disability or any other basis prohibited by law.

The representation of females/males as well as other groups at management levels is based on skills and experience. Target representation for the Board of Directors is one out of three. Currently in the Board of Directors the representation is one out of two. The Company does not have any employees, thus no target has been set for other management levels.
The Company has not established policies regarding respect of human rights and to reduce the climate impact of the business. However, the Company has as a sales and administrative company only limited impact on the climate.

Actions taken

Compliance with company and regulatory requirements is a strategic priority for Actavis. A compliance issue management system has been established to keep track of any issues or potential issues identified during due diligence assessments, Corporate EHS Audits, etc. Compliance results are considered a key measure of a company's performance and these are closely tracked and results communicated regularly to senior management. The Management of drug safety and side effect department (pharmacovigilance) has during 2014 been situated in Actavis, Copenhagen and Stockholm.

Goals achieved

Actavis has once again been recognized for its environmental commitment, earning top marks in the Carbon Disclosure Project's 2014 S&P 500 Climate Change Report. The CDP list is one of the most widely recognized indicators of company commitment to integrating climate change risk management into strategic planning, taking action toward emissions reductions and demonstrating a long-term view of how to best manage the assets of shareholders. In this year's rankings, Actavis scored among the top three of 80 companies reporting in the Healthcare Industry, behind Johnson & Johnson and Bristol Myers Squibb and ahead of companies including Pfizer, Allergan, Merck, Eli Lilly, Amgen and Hospira.

Management's review

Uncertainties relating to recognition and measurement

Part of the Company's transactions is settled in foreign currencies. Therefore, changes in foreign exchange rates have a considerable effect on recognition and measurement.

Interest rate risks primarily relate to the Company's interest-bearing debt to group enterprises. The debt carries a floating interest rate.

Hedging of interest rate and currency risks is handled by Group Treasury.

Unusual events

In the opinion of Management, the financial statements are not affected by any exceptional circumstances.

Subsequent Events

On Mar 17, 2015, the acquisition of Allergan was finalized. The combination has received the approval of the shareholders of both companies. Actavis has announced its intention to name the combined Company Allergan, with the Actavis name remaining in selected geographies. The changes await shareholder approval.

On Mar 27, 2015, Actavis Group ehf, sold its 1 share of Actavis Nordic A/S to Actavis Holding NWE B.V. for 1 DKK.

Accounting policies

The annual report of Actavis Nordic A/S for 2014 has been prepared in accordance with the provisions of the Danish Financial Statements Act applying to large enterprises of reporting class C.

The accounting policies applied are consistent with those applies last year.

The annual report for 2014 is presented in TDKK.

In pursuance of section 112(1) and section 86(4) of the Danish Financial Statements Act, consolidated financial statements and cash flow statement have not been prepared. The financial statements of Actavis Nordic A/S are included in the consolidated financial statements of Actavis plc., US.

Upon group internal acquisitions of subsidiaries, the residual between cost price and booked equity in the acquired company at the point of acquisition is calculated after individual assets and liabilities are adjusted to fair value (purchase method). Any decided restructuring cost in regards to the acquired company is deducted. Upon group merger the purchase method is also used.

Any residuals, positive and negative, in amounts as a result of change in recognition and measurement of net assets can be regulated until the end of the fiscal year after the year of acquisition. These regulations are also reflected in the value of goodwill or negative goodwill, including already booked depreciation.

Error in previous years

Comparative figures for 2013 are restated as a result of a grant of DKK 43.8 million received in connection with acquisition of a subsidiary. The grant has historically been classified as debt to group enterprises, but should have been recognised as a grant over equity. This is corrected as an error in previous years, and had the following effect:

TDKK	Annual Report 2013	Restated
Equity	-52,707	-8.944
Long-term debt	368.668	324,905

The reclassification had no effect on the income statement og total assets.

Accounting policies

Basis of recognition and measurement

Income is recognised in the income statement as earned, including value adjustments of financial assets and liabilities. All expenses, including amortisation, depreciation and impairment losses, are also recognised in the income statement.

Assets are recognised in the balance sheet when it is probable that future economic benefits will flow to the Company and the value of the asset can be measured reliably.

Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow from the Company and the value of the liability can be measured reliably.

On initial recognition, assets and liabilities are measured at cost. On subsequent recognition, assets and liabilities are measured as described below for each individual accounting item. .

Certain financial assets and liabilities are measured at amortised cost using the effective interest method. Amortised cost is calculated as the historic cost less any instalments and plus/less the accumulated amortisation of the difference between the cost and the nominal amount.

On recognition and measurement, allowance is made for predictable losses and risks which occur before the annual report is presented and which confirm or invalidate matters existing at the balance sheet date.

Foreign currency translation

On initial recognition, foreign currency transactions are translated applying the exchange rate at the transaction date. Foreign-exchange differences arising between the exchange rates at the transaction date and at the date of payment are recognised in the income statement as financial income or financial expenses.

Receivables and payables and other monetary items denominated in foreign currencies are translated at the exchange rates at the balance sheet date. The difference between the exchange rates at the balance sheet date and the date at which the receivable or payable arose or was recognised in the latest financial statements is recognised in the income statement as financial income or financial expenses.

Income statement

Revenue

Revenue from the sale of goods for resale and finished goods is recognised in the income statement, provided that the transfer of risk, usually on delivery to the buyer, has taken place and that the income can be measured reliably and is expected to be received.

Accounting policies

Revenue is measured at the fair value of the agreed consideration, excluding VAT and other indirect taxes charged on behalf of third parties. All discounts granted are recognised in revenue.

Cost of goods

Cost of goods include the raw materials and consumables used in generating the year's revenue.

Other external expenses

Other external expenses include expenses related to distribution, sale, administration, premises, bad debts, etc.

Financial income and expenses

Financial income and expenses include interest and realised and unrealised exchange adjustments.

Income from investments in subsidiaries

Dividend from investments is recognised in the reporting year in which the dividend is declared.

Tax on profit/loss for the year

Tax for the year, which comprises the current tax charge for the year and changes in the deferred tax charge, including changes arising from changes in tax rates, is recognised in the income statement as regards the portion that relates to entries directly in equity.

Balance sheet

Intangible assets

On initial recognition, intangible assets are measured at cost.

Product rights acquired are measured at the lower of cost less accumulated amortisation and recoverable amount. The amortisation period is five years and amortisation is commenced when the product rights are put to use.

Accounting policies

Impairment of fixed assets

The carrying amount of intangible assets are reviewed on an annual basis to determine whether there is any indication of impairment other than that expressed by amortisation and depreciation.

If so, the asset is written down to its lower recoverable amount.

Investments in subsidiaries

Investment in subsidiaries are measured at cost. Where the cost exceeds the net realisable value, the carrying amount is reduced to such lower value.

Subsidiaries with a negative net asset value are recognised at DKK 0. Any legal or constructive obligation of the Parent Company to cover the negative balance of the enterprise is recognised in provision.

Dividends received are recognised in the income statement in the financial year in which they are declared. If proposed dividends exceed accumulated earnings after the acquisition date, dividends are however recognised as a reduction of the cost of the investments.

The carrying amount of investments in subsidiaries is subject to an annual test for indications of impairment. Write-down is made to the recoverable amount if this is lower than the carrying amount.

Impairment losses are recognised in the income statement.

Stocks

Stocks are measured at using FIFO method Where the net realisable value is lower than the cost, inventories are carried at this lower value.

The net realisable value of stocks is calculated at the amount expected to be generated by sale in the process of normal operations with deduction of selling expenses and costs of completion. The net realisable value is determined allowing for marketability, obsolescene and development in expected sales sum.

The cost of goods for resale, raw materials and consumables equals landed costs.

The cost of finished goods and work in progress are measured at cost, comprising the cost of raw materials, consumables, direct wages and salaries and indorect production overheads. Indirect production overheads comprise indirect materials and wages and salaries.

Accounting policies

Receivables

Receivables are measured in the balance sheet at the lower of amortised cost and net realisable value, which corresponds to nominal value less provisions for bad debt. Provisions for bad debts are determined on the basis of an individual assessment of each receivable, and in respect of trade receivables, a general provision is also made based on the Company's experience from previous years.

Prepayments

Prepayments comprise costs incurred concerning subsequent financial years.

Income tax and deffered tax

Actavis Nordic A/S assumes, in its capacity as management company, the liability for the subsidiaries' payment of income tax to the tax authorities as the joint taxation contributions of the subsidiaries are received.

Current tax liabilities and current tax receivables are recognised in the balance sheet as the estimated tax on the taxable income for the year, adjusted for tax on the taxable income for previous years and tax paid on account.

Joint taxation contributions payable and receivable are recognised in the balance sheet as income tax receivable or income tax payable, respectively.

Deferred tax is measured according to the liability method on all temporary differences between the carrying amount and the tax base of assets and liabilities.

Deferred tax is adjusted for elimination of unrealised intra-group gains and losses.

Deferred tax is measured on the basis of the taxation rules and taxation rates applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax.

Liabilities

Financial liabilities are recognised on the raising of the loan at the proceeds received net of transaction costs incurred. On subsequent recognition, the financial liabilities are measured at amortised cost, corresponding to the capitalised value, using the effective interest method. Accordingly, the difference between the proceeds and the nominal value is recognised in the income statement over the term of the loan.

Other debts are measured at net realisable value.

Accounting policies

Financial highlights

Definitions of financial ratios

Gross margin ratio	Gross Profit x 100 / Revenue
Solvency ratio	Equity at year end x 100 / Total assets
Return on equity	Net profit for the year x 100 / Average equity

Income statement 1 January - 31 December

	Note	2014 TDKK	2013 TDKK
Revenue		**357.410**	**359.411**
Cost of goods		-312.392	-320.801
Other external expenses		-41.068	-53.251
Gross profit		**3.950**	**-14.641**
Depreciation, amortisation and impairment of intangible assets		-162	-192
Profit/loss before financial income and expenses		**3.788**	**-14.833**
Income from investments in subsidiares	3	-763	-118.299
Financial income	4	286	303
Financial costs	5	-19.743	-70.611
Profit/loss before tax		**-16.432**	**-203.440**
Tax on profit/loss for the year	6	412	1.446
Net profit/loss for the year		**-16.020**	**-201.994**
Proposed distribution of profit			
Retained earnings		-16.020	-201.994
		-16.020	**-201.994**

Balance sheet at 31 December

	Note	2014 TDKK	2013 TDKK
Assets			
Acquired patents		36	198
Intangible assets	7	**36**	**198**
Investments in subsidiaries	8	205.986	249.749
Fixed asset investments		**205.986**	**249.749**
Fixed assets		**206.022**	**249.947**
Raw materials and consumables		98.356	141.427
Stocks		**98.356**	**141.427**
Receivables from subsidiaries		19.018	17.436
Other receivables		0	579
Corporation tax		2.734	3.066
Prepayments		1.244	56
Receivables		**22.996**	**21.137**
Cash at bank and in hand		**2.679**	**1.334**
Current assets total		**124.031**	**163.898**
Assets total		**330.053**	**413.845**

Balance sheet at 31 December

	Note	2014 TDKK	2013 TDKK
Liabilities and equity			
Share capital		951	951
Retained earnings		-22.088	-9.895
Equity total	9	**-21.137**	**-8.944**
Payables to subsidiaries		278.167	324.905
Long-term debt	10	**278.167**	**324.905**
Trade payables		23.833	14.998
Payables to subsidiaries	10	47.008	76.697
Corporation tax		0	3.042
Other payables		2.182	3.147
Short-term debt		**73.023**	**97.884**
Debt total		**351.190**	**422.789**
Liabilities and equity total		**330.053**	**413.845**
Capital position	1		
Fee to auditors appointed at the general meeting	12		
Contingent liabilities	11		
Related parties and ownership	13		

Notes to the Annual Report

1 Capital position

In consequence of the negative results and because equity is negative in the amount of DKK 21,137k, the Company is subject to the capital loss provisions of the Danish Companies Act.

Actavis Group ehf. has issued a Letter of Support in which it is stated the they will support the Company financially to the extent necessary to finance its operating activities and to settle its financial obligations, and that the Actavis Group will subordinate their receivables in favour of other creditors. The Letter of Support is effectice until 20 June 2016.

Therefore, it is the opinion of the Board of Directors and the Executive Board that based on the Letter of Support the Company's capital resources are sufficient for the Company to continue as a going concern, and consequently, the Annual Report is prepared based on a going concern assumption.

In 2015, the Company's shareholders will decide on the future capital structure of the Company, including how to solve the capital loss issue.

2 Information on segments

Geographical segment

TDKK	Denmark	Finland	Sweden	Others	Total
2014					
Revenue	168.814	161.945	22.821	3.830	357.410
2013					
Revenue	190.413	141.771	21.825	5.402	359.411

	2014 TDKK	2013 TDKK
3 Income from investments in subsidiares		
Loss from sale of subsidiary	-763	0
Impairment of subsidiaries	0	-168.299
Dividend	0	50.000
	-763	**-118.299**

Notes to the Annual Report

		2014 TDKK	2013 TDKK
4	**Financial income**		
	Other financial income	0	1
	Exchange gains	286	302
		286	**303**
5	**Financial costs**		
	Interest paid to subsidiaries	19.363	70.115
	Other financial costs	1	0
	Exchange loss	379	496
		19.743	**70.611**
6	**Tax on profit/loss for the year**		
	Current tax for the year	-2.734	-1.381
	Adjustment of tax concerning previous years	2.322	-65
		-412	**-1.446**

The Company has a deferred tax asset in the amount of DKK 75.2 million at 31 December 2014 (2013: 59.1 million) relating to non-current assets and tax loss carryforwards. Due to uncertainty to the timing of future utilisation, the deferred tax asset is recognised af DKK 0.

7 Intangible assets

	Acquired patents
Cost at 1 January 2014	65.376
Cost at 31 December 2014	65.376
Af- og nedskrivninger at 1 January 2014	65.178
Depreciation for the year	162
Af- og nedskrivninger at 31 December 2014	65.340
Carrying amount at 31 December 2014	**36**

		2014 TDKK	2013 TDKK
8	**Investments in subsidiaries**		
	Cost at 1 January 2014	2.222.691	2.174.202
	Additions for the year	0	48.489
	Disposals for the year	-43.763	0
	Cost at 31 December 2014	2.178.928	2.222.691
	Revaluations at 1 January 2014	-1.972.942	-1.624.643
	Dividend to the Parent Company	0	-180.000
	Revaluations for the year, net	0	-168.299
	Revaluations at 31 December 2014	-1.972.942	-1.972.942
	Carrying amount at 31 December 2014	**205.986**	**249.749**

Investments in subsidiaries are specified as follows:

Name	Place of registered office	Share capital	Votes and ownership	Equity	Net profit/loss for the year
Actavis Holding AB	Sweden	SEK 1.000.000	100%	76.588	1.609
Actavis A/S	Denmark	DKK 884.000	100%	14.609	-10.680
Actavis OY	Finland	EUR 16.000	100%	-1.120	451
UAB Actavis Baltic	Lithuania	EUR 10.000	100%	2.971	743
Actavis Holding Germany GmbH	Germany	EUR 25.500	100%	1.504	491

9 Equity

	Share capital	Retained earnings	Total
Equity at 1 January 2014	951	-53.658	-52.707
Net effect from adjustment of fundamental error	0	43.763	43.763
Adjusted equity at 1 January 2014	951	-9.895	-8.944
Addition, merger	0	3.827	3.827
Net profit/loss for the year	0	-16.020	-16.020
Equity at 31 December 2014	**951**	**-22.088**	**-21.137**

The share capital consists of 951.004 shares of a nominal value of DKK 1. No shares carry any special rights.

During the last 5 years the share capital has been increased with DKK 1 in 2012, DKK 2 in 2013 and DKK 1 in 2014.

10 Long term debt

	2014 TDKK	2013 TDKK
Payables to subsidiaries		
Between 1 and 5 years	278.167	324.905
Non-current portion	278.167	324.905
Other short-term debt to subsidiaries	47.008	76.697
Current portion	47.008	76.697
	325.175	**401.602**

11 Contingent liabilities

The Company has entered into a series of contracts for product rights under which the Company is to pay for the rights if they are applied on export markets.

	2014 TDKK	2013 TDKK
12 Fee to auditors appointed at the general meeting		
PricewaterhouseCoopers:		
Audit fee	256	170
Non-audit services	188	35
	444	**205**

13 Related parties and ownership

Ownership

According to the Company's register of shareholders, the following shareholders hold a minimum of 5% of the voting rights or a minimum of 5% of the share capital:

Actavis Holding NWE B.V., Netherland

Consolidated financial statements

Actavis Nordic A/S is included in the consolidated financial statements of Actavis plc., US.

The consolidated financial statements of Actavis plc., US, can be obtained via the Group Company's homepage: www.actavis.com